For UK-based patients with Type 1 diabetes, the Dexcom G6
rtCGM device is associated with significant improvements in
clinical outcomes[1],[2] and is highly-cost effective
over patient lifetimes
EDINBURGH, Scotland,
Sept. 29, 2020 /PRNewswire/
-- DexCom, Inc. (NASDAQ: DXCM), the leader in continuous
glucose monitoring (CGM) for people with diabetes, announced today
the publication of its paper, "Long-term Cost-effectiveness of
Dexcom G6 Real-time Continuous Glucose Monitoring in Patients with
Type 1 Diabetes in the UK" in Diabetes Care.
rtCGM is associated with significant improvement in glycaemic
control and reduced incidence of hypoglycaemic
events[1],[2] relative to fingerstick testing,
but higher acquisition costs. A long-term health economic analysis
was performed to establish the long-term cost-effectiveness of
rtCGM (Dexcom G6) versus fingerstick testing alone in UK-based
patients with Type 1 diabetes.
Key findings from the study include:
- Over patient lifetimes Dexcom G6 has been proven to be a highly
cost-effective disease management option for patients with Type 1
diabetes, relative to self-monitoring of blood glucose (SMBG), also
known as fingerstick testing
- It has been proven that Dexcom G6 falls well below the National
Institute for Health and Care Excellence (NICE) willingness to pay
threshold of £20,000 per quality-adjusted life years (QALY) gained
with an incremental cost-effectiveness ratio of £9,558 per QALY
gained
- For UK-based patients with Type 1 diabetes, the Dexcom G6
device is associated with significant improvements in HbA1c and
hypoglycaemia leading to improved quality of life and clinical
outcomes for people with Type 1 diabetes
- In the overall Type 1 diabetes population, Dexcom G6 was
associated with an average incremental gain in quality-adjusted
life expectancy of 1.49 QALYs compared with SMBG
- The cost-effectiveness of Dexcom G6 was sensitive to capture
the quality of benefits associated with reduced fear of
hypoglycaemia and avoidance of fingerstick testing,* as
well as the HbA1c benefit associated with rtCGM use
"The results of the UK Dexcom G6 cost effectiveness analysis,
clearly demonstrates that rtCGM is not only good value for money
but also a highly cost-effective intervention for people with
uncontrolled diabetes," said Peter
Lynch, vice president of global access at Dexcom. "This
publication provides NICE with a robust economic analysis that
along with our extensive clinical evidence should enable them to
produce a Technology Appraisal on the Dexcom G6. This will support
National Health Service England in providing equal access to rtCGM
thus reducing the inconsistent postcode prescribing that is
currently seen across NHS England."
Additionally, Dexcom is one of four industry partners in the
Pathway to Choice programme led by Type 1 diabetes charity
JDRF. The first Pathway to Choice report, launched in
February 2020, revealed that 83% of
people affected by Type 1 diabetes would like to use continuous
glucose monitoring through the NHS, but there are clear barriers to
access.
"We created the Pathway to Choice partnership to build
awareness and access to Type 1 technology choices for people with
Type 1 diabetes," said Karen
Addington, CEO of JDRF UK. "Greater choice around wearable
technologies could make a real difference to people living with
this relentless and demanding condition."
Based on the hypoglycaemia criterion alone, it is estimated that
up to one quarter of patients with Type 1 diabetes may be eligible
for Dexcom G6. Similarly, it is estimated that up to 70% of
patients with Type 1 diabetes patients in England and Wales may be eligible for Dexcom
G6[1].
"Despite the guidance issued by NICE, funding for Dexcom G6 is
not universally available," said Mr. Lynch. "In one recent study in
patients and caregivers, 23% of Dexcom G6 users reported only
partial NHS funding and 26% were wholly self-funded. This inequity
in funding suggests the initial acquisition cost of Dexcom G6 may
be a barrier to widespread adoption of its use in the UK."
Long-term health economic analyses suggest that Dexcom G6
improves glycaemic control and reduces the risk for long-term
diabetes-related complications[2],[3]. This
represents a cost-effective management option, particularly for
patients meeting the NICE eligibility criteria for Dexcom G6.
Methodology
The analysis was performed using the IQVIA CORE Diabetes Model
(IQVIA, Basel, Switzerland).
Patient cohort characteristics and clinical input data were sourced
from the DIAMOND trial in adults with Type 1 diabetes and
simulations were performed separately in the overall population of
Type 1 diabetes patients with baseline HbA1c ≥7.5%. The analysis
was performed from the NHS healthcare payer perspective over a
lifetime time horizon. Future costs and clinical outcomes were
discounted at 3.5% per annum.
About DexCom, Inc.
Dexcom, Inc. empowers people to take control of diabetes through
innovative continuous glucose monitoring (CGM) systems.
Headquartered in San Diego,
Calif., and with operations in Europe, Dexcom has emerged as a leader of
diabetes care technology. By listening to the needs of users,
caregivers, and providers, Dexcom simplifies and improves diabetes
management around the world.
*If your glucose alerts and readings from
Dexcom G6 do not match symptoms or expectations, use a blood
glucose meter to make diabetes treatment decisions.
1. https://files.digital.nhs.uk/E0/030704/National%20Diabetes%20Insulin%20Pump%20Audit%202017-18%20Report%20v2.pdf
2. JAMA. 2017;317(4):371-378.
3. Welsh, J.B. et al (2019). "Accuracy, Utilization, and
Effectiveness Comparisons of Different Continuous Glucose
Monitoring Systems." Diabetes Technol Ther 21(3) Dexcom, Dexcom G6,
Dexcom Share, and Dexcom CLARITY are registered trademarks of
Dexcom, Inc. in the United States
and/or other countries.
© 2020 Dexcom, Inc. Dexcom, Dexcom G6 and Dexcom Follow are
registered trademarks of Dexcom, Inc. in the U.S., and may be
registered in other countries. All rights reserved.
Logo -
https://mma.prnewswire.com/media/553571/Dexcom_Logo.jpg
